Short Interest in Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Drops By 11.0%

Basilea Pharmaceutica AG (OTCMKTS:BPMUF) was the recipient of a large decline in short interest in the month of December. As of December 15th, there was short interest totalling 25,000 shares, a decline of 11.0% from the November 30th total of 28,100 shares. Based on an average daily volume of 0 shares, the short-interest ratio is presently ∞ days.

Analyst Upgrades and Downgrades

Separately, HC Wainwright raised shares of Basilea Pharmaceutica to a “strong-buy” rating in a research note on Monday, September 23rd.

Basilea Pharmaceutica Stock Performance

BPMUF stock remained flat at $52.83 during midday trading on Tuesday. Basilea Pharmaceutica has a twelve month low of $38.60 and a twelve month high of $52.83. The business’s fifty day moving average price is $52.83 and its two-hundred day moving average price is $50.70.

About Basilea Pharmaceutica

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.